Yuki Fujiwara
Concepts (388)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Macrophages | 33 | 2026 | 1532 | 2.830 |
Why?
| | Sialic Acid Binding Ig-like Lectin 1 | 6 | 2026 | 11 | 2.070 |
Why?
| | B7-H1 Antigen | 15 | 2026 | 245 | 1.890 |
Why?
| | Tumor Microenvironment | 19 | 2026 | 747 | 1.550 |
Why?
| | Antigens, Differentiation, Myelomonocytic | 6 | 2025 | 66 | 1.470 |
Why?
| | Macrophage Activation | 9 | 2025 | 182 | 1.340 |
Why?
| | Receptors, Cell Surface | 6 | 2025 | 371 | 1.270 |
Why?
| | Antigens, CD | 7 | 2025 | 560 | 1.210 |
Why?
| | Neoplasms | 10 | 2026 | 2954 | 1.030 |
Why?
| | Lymph Nodes | 8 | 2026 | 511 | 1.000 |
Why?
| | Receptors, G-Protein-Coupled | 3 | 2024 | 233 | 0.920 |
Why?
| | Immunotherapy | 11 | 2026 | 671 | 0.890 |
Why?
| | Flavanones | 3 | 2026 | 7 | 0.820 |
Why?
| | Immunity | 3 | 2021 | 141 | 0.820 |
Why?
| | Mice | 47 | 2026 | 18297 | 0.790 |
Why?
| | Hepatoblastoma | 4 | 2025 | 52 | 0.770 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 6 | 2026 | 156 | 0.740 |
Why?
| | Liver Neoplasms | 6 | 2025 | 776 | 0.740 |
Why?
| | Cell Line, Tumor | 22 | 2025 | 3545 | 0.720 |
Why?
| | Antineoplastic Agents | 5 | 2024 | 2219 | 0.680 |
Why?
| | Animals | 54 | 2026 | 38107 | 0.650 |
Why?
| | Carcinoma, Renal Cell | 5 | 2025 | 231 | 0.650 |
Why?
| | Hyaluronan Receptors | 2 | 2018 | 105 | 0.630 |
Why?
| | Lung Neoplasms | 9 | 2026 | 2675 | 0.620 |
Why?
| | Colorectal Neoplasms | 6 | 2026 | 874 | 0.610 |
Why?
| | Atherosclerosis | 4 | 2024 | 410 | 0.610 |
Why?
| | Immunologic Factors | 2 | 2018 | 244 | 0.590 |
Why?
| | Kidney Neoplasms | 5 | 2025 | 419 | 0.570 |
Why?
| | Chemokine CXCL10 | 3 | 2024 | 39 | 0.560 |
Why?
| | Thalidomide | 1 | 2018 | 43 | 0.550 |
Why?
| | Orosomucoid | 3 | 2025 | 10 | 0.550 |
Why?
| | Diosgenin | 1 | 2018 | 2 | 0.540 |
Why?
| | Saponins | 1 | 2018 | 12 | 0.540 |
Why?
| | Immunomodulation | 1 | 2018 | 98 | 0.520 |
Why?
| | T-Lymphocytes | 2 | 2026 | 2012 | 0.510 |
Why?
| | Cell Proliferation | 13 | 2025 | 2502 | 0.510 |
Why?
| | Plant Extracts | 2 | 2025 | 192 | 0.510 |
Why?
| | Colonic Neoplasms | 4 | 2024 | 259 | 0.500 |
Why?
| | Extracellular Matrix Proteins | 1 | 2018 | 156 | 0.480 |
Why?
| | Breast Neoplasms | 4 | 2023 | 2418 | 0.460 |
Why?
| | Inducible T-Cell Co-Stimulator Protein | 2 | 2026 | 12 | 0.460 |
Why?
| | Programmed Cell Death 1 Receptor | 5 | 2025 | 268 | 0.450 |
Why?
| | Anti-Inflammatory Agents | 3 | 2026 | 474 | 0.450 |
Why?
| | Biomarkers, Tumor | 9 | 2026 | 1339 | 0.450 |
Why?
| | Acetylcysteine | 2 | 2026 | 139 | 0.440 |
Why?
| | Sulfides | 2 | 2026 | 92 | 0.440 |
Why?
| | Mice, Inbred C57BL | 18 | 2026 | 6034 | 0.430 |
Why?
| | Foam Cells | 4 | 2022 | 17 | 0.410 |
Why?
| | Glycation End Products, Advanced | 3 | 2020 | 84 | 0.410 |
Why?
| | Cell Communication | 6 | 2023 | 327 | 0.400 |
Why?
| | Cholangiocarcinoma | 2 | 2025 | 110 | 0.380 |
Why?
| | Bile Duct Neoplasms | 2 | 2025 | 132 | 0.380 |
Why?
| | Humans | 66 | 2026 | 146342 | 0.370 |
Why?
| | Neuroendocrine Tumors | 2 | 2025 | 122 | 0.360 |
Why?
| | Membrane Glycoproteins | 2 | 2025 | 495 | 0.360 |
Why?
| | Tomatine | 1 | 2012 | 1 | 0.360 |
Why?
| | Sterol O-Acyltransferase | 1 | 2012 | 6 | 0.360 |
Why?
| | Liver | 4 | 2026 | 1864 | 0.360 |
Why?
| | Hyperlipidemias | 2 | 2014 | 120 | 0.360 |
Why?
| | Apolipoproteins E | 1 | 2012 | 97 | 0.340 |
Why?
| | Macrophages, Peritoneal | 2 | 2024 | 89 | 0.340 |
Why?
| | Pancreatic Neoplasms | 3 | 2025 | 944 | 0.330 |
Why?
| | Plaque, Atherosclerotic | 2 | 2024 | 60 | 0.330 |
Why?
| | Down-Regulation | 2 | 2017 | 614 | 0.330 |
Why?
| | T-Lymphocyte Subsets | 2 | 2026 | 416 | 0.310 |
Why?
| | Gene Expression Regulation, Neoplastic | 5 | 2024 | 1432 | 0.310 |
Why?
| | Mice, Knockout | 8 | 2026 | 3125 | 0.310 |
Why?
| | STAT3 Transcription Factor | 5 | 2023 | 214 | 0.310 |
Why?
| | Melanoma, Experimental | 2 | 2022 | 106 | 0.300 |
Why?
| | Aorta | 3 | 2024 | 440 | 0.300 |
Why?
| | Carcinoma, Squamous Cell | 3 | 2024 | 628 | 0.300 |
Why?
| | Thiophenes | 3 | 2023 | 117 | 0.290 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 3 | 2022 | 1195 | 0.280 |
Why?
| | Programmed Cell Death 1 Ligand 2 Protein | 2 | 2025 | 14 | 0.280 |
Why?
| | Small Cell Lung Carcinoma | 2 | 2023 | 125 | 0.280 |
Why?
| | Ligands | 4 | 2025 | 678 | 0.270 |
Why?
| | Interferon-alpha | 3 | 2025 | 201 | 0.260 |
Why?
| | CD4-Positive T-Lymphocytes | 2 | 2025 | 1150 | 0.250 |
Why?
| | Chemokine CCL20 | 1 | 2026 | 6 | 0.250 |
Why?
| | Disease Models, Animal | 10 | 2026 | 4580 | 0.250 |
Why?
| | Porphyromonas gingivalis | 1 | 2026 | 23 | 0.240 |
Why?
| | Cross-Priming | 1 | 2026 | 17 | 0.240 |
Why?
| | Neoplastic Syndromes, Hereditary | 2 | 2024 | 47 | 0.240 |
Why?
| | Immunohistochemistry | 3 | 2025 | 1712 | 0.240 |
Why?
| | Adhesins, Bacterial | 1 | 2026 | 46 | 0.240 |
Why?
| | Brain Neoplasms | 3 | 2025 | 1325 | 0.240 |
Why?
| | Cysteine Endopeptidases | 1 | 2026 | 81 | 0.240 |
Why?
| | Receptors, Antigen, T-Cell, gamma-delta | 1 | 2026 | 103 | 0.240 |
Why?
| | Vacuoles | 1 | 2026 | 36 | 0.240 |
Why?
| | Nephritis, Hereditary | 1 | 2026 | 3 | 0.240 |
Why?
| | Syndecan-1 | 1 | 2026 | 42 | 0.230 |
Why?
| | Tumor Necrosis Factor Ligand Superfamily Member 15 | 1 | 2026 | 8 | 0.230 |
Why?
| | Monocytes | 3 | 2025 | 538 | 0.230 |
Why?
| | Antigens, CD7 | 1 | 2025 | 2 | 0.230 |
Why?
| | Mycobacterium avium | 1 | 2026 | 21 | 0.230 |
Why?
| | Antigen-Presenting Cells | 1 | 2026 | 161 | 0.230 |
Why?
| | Signal Transduction | 11 | 2025 | 5246 | 0.230 |
Why?
| | Apyrase | 1 | 2025 | 27 | 0.230 |
Why?
| | Mice, Inbred BALB C | 3 | 2025 | 1244 | 0.230 |
Why?
| | Thyroid Nuclear Factor 1 | 1 | 2025 | 16 | 0.230 |
Why?
| | Interleukin-6 | 4 | 2026 | 784 | 0.230 |
Why?
| | Proteinuria | 1 | 2026 | 103 | 0.230 |
Why?
| | Interleukins | 2 | 2025 | 248 | 0.220 |
Why?
| | Chondrosarcoma | 1 | 2025 | 17 | 0.220 |
Why?
| | Prognosis | 9 | 2026 | 4351 | 0.220 |
Why?
| | Immune Evasion | 1 | 2026 | 64 | 0.220 |
Why?
| | HTLV-I Infections | 1 | 2025 | 29 | 0.220 |
Why?
| | Orthomyxoviridae Infections | 1 | 2026 | 72 | 0.220 |
Why?
| | Female | 29 | 2026 | 79499 | 0.220 |
Why?
| | Kidney Glomerulus | 1 | 2026 | 129 | 0.220 |
Why?
| | Carcinoma, Papillary | 1 | 2025 | 83 | 0.220 |
Why?
| | Isocitrate Dehydrogenase | 1 | 2025 | 71 | 0.220 |
Why?
| | Adenocarcinoma, Mucinous | 1 | 2025 | 76 | 0.210 |
Why?
| | Neoadjuvant Therapy | 2 | 2025 | 475 | 0.210 |
Why?
| | Interleukin-10 | 3 | 2021 | 310 | 0.210 |
Why?
| | Macrophage Colony-Stimulating Factor | 2 | 2022 | 20 | 0.210 |
Why?
| | Chemical and Drug Induced Liver Injury | 1 | 2026 | 138 | 0.210 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 2 | 2022 | 158 | 0.210 |
Why?
| | Histocompatibility Antigens Class I | 1 | 2026 | 207 | 0.210 |
Why?
| | Histocompatibility Antigens Class II | 1 | 2026 | 365 | 0.210 |
Why?
| | Lymphoma, Large-Cell, Anaplastic | 1 | 2024 | 23 | 0.200 |
Why?
| | Diet, High-Fat | 1 | 2025 | 267 | 0.200 |
Why?
| | Carcinoma, Embryonal | 1 | 2023 | 3 | 0.200 |
Why?
| | Photochemotherapy | 1 | 2024 | 39 | 0.200 |
Why?
| | Clodronic Acid | 1 | 2023 | 19 | 0.190 |
Why?
| | Aortic Diseases | 1 | 2024 | 125 | 0.190 |
Why?
| | AMP-Activated Protein Kinases | 1 | 2024 | 193 | 0.190 |
Why?
| | Nutritional Status | 1 | 2026 | 346 | 0.190 |
Why?
| | Neovascularization, Pathologic | 1 | 2025 | 287 | 0.190 |
Why?
| | Acetaminophen | 1 | 2026 | 268 | 0.190 |
Why?
| | Male | 29 | 2026 | 73396 | 0.190 |
Why?
| | Phenotype | 4 | 2025 | 3206 | 0.190 |
Why?
| | beta-Cyclodextrins | 1 | 2023 | 32 | 0.190 |
Why?
| | Up-Regulation | 1 | 2026 | 841 | 0.190 |
Why?
| | Subarachnoid Hemorrhage | 1 | 2023 | 74 | 0.180 |
Why?
| | Drug Resistance, Neoplasm | 2 | 2025 | 893 | 0.180 |
Why?
| | T-Lymphocytes, Cytotoxic | 4 | 2026 | 180 | 0.180 |
Why?
| | Chemokine CXCL13 | 1 | 2022 | 15 | 0.180 |
Why?
| | Neoplasms, Germ Cell and Embryonal | 1 | 2023 | 76 | 0.180 |
Why?
| | Bone Neoplasms | 1 | 2025 | 272 | 0.180 |
Why?
| | Endoplasmic Reticulum Stress | 2 | 2020 | 120 | 0.180 |
Why?
| | Receptor, Macrophage Colony-Stimulating Factor | 1 | 2022 | 12 | 0.180 |
Why?
| | Multiple Myeloma | 1 | 2026 | 310 | 0.180 |
Why?
| | Testicular Neoplasms | 1 | 2023 | 108 | 0.180 |
Why?
| | Cisplatin | 1 | 2024 | 347 | 0.180 |
Why?
| | Melanoma | 2 | 2022 | 765 | 0.180 |
Why?
| | Tumor Necrosis Factor-alpha | 3 | 2022 | 1224 | 0.180 |
Why?
| | Receptors, CXCR3 | 1 | 2022 | 17 | 0.180 |
Why?
| | Immune System Diseases | 1 | 2022 | 43 | 0.180 |
Why?
| | Chemokine CXCL9 | 1 | 2022 | 38 | 0.170 |
Why?
| | Sulfur Compounds | 1 | 2021 | 7 | 0.170 |
Why?
| | Carcinoma, Pancreatic Ductal | 1 | 2025 | 297 | 0.170 |
Why?
| | Heparin-binding EGF-like Growth Factor | 1 | 2021 | 16 | 0.170 |
Why?
| | Gene Expression | 1 | 2026 | 1463 | 0.170 |
Why?
| | Cell Line | 5 | 2024 | 2814 | 0.170 |
Why?
| | Osteopontin | 1 | 2021 | 37 | 0.170 |
Why?
| | Sulfoxides | 2 | 2023 | 4 | 0.170 |
Why?
| | Interleukin-12 | 2 | 2022 | 115 | 0.170 |
Why?
| | CD47 Antigen | 1 | 2021 | 41 | 0.170 |
Why?
| | ATP-Binding Cassette Transporters | 1 | 2022 | 117 | 0.170 |
Why?
| | Neuropeptides | 1 | 2021 | 76 | 0.170 |
Why?
| | Glioblastoma | 1 | 2025 | 350 | 0.170 |
Why?
| | Aged, 80 and over | 8 | 2026 | 8391 | 0.170 |
Why?
| | Adipose Tissue | 1 | 2025 | 642 | 0.170 |
Why?
| | Mycobacterium Infections, Nontuberculous | 1 | 2026 | 339 | 0.170 |
Why?
| | Mouth Neoplasms | 1 | 2022 | 88 | 0.170 |
Why?
| | Disease Progression | 7 | 2026 | 2867 | 0.160 |
Why?
| | Phagocytes | 1 | 2021 | 79 | 0.160 |
Why?
| | Interleukin-1beta | 2 | 2026 | 397 | 0.160 |
Why?
| | Immunotherapy, Adoptive | 1 | 2025 | 356 | 0.160 |
Why?
| | Burns, Electric | 1 | 2020 | 25 | 0.160 |
Why?
| | Pneumonia, Viral | 1 | 2026 | 387 | 0.160 |
Why?
| | Penicillium | 1 | 2020 | 8 | 0.160 |
Why?
| | Immune Tolerance | 1 | 2023 | 386 | 0.160 |
Why?
| | Neoplastic Cells, Circulating | 1 | 2021 | 81 | 0.160 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2024 | 530 | 0.150 |
Why?
| | Carcinoma, Hepatocellular | 1 | 2024 | 370 | 0.150 |
Why?
| | Epithelial Cells | 1 | 2026 | 1119 | 0.150 |
Why?
| | Protective Agents | 1 | 2020 | 43 | 0.150 |
Why?
| | Pharmaceutical Preparations | 1 | 2021 | 172 | 0.150 |
Why?
| | Osteoblasts | 1 | 2020 | 145 | 0.150 |
Why?
| | Cell Movement | 3 | 2022 | 951 | 0.150 |
Why?
| | Oxadiazoles | 1 | 2019 | 33 | 0.140 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 1 | 2026 | 928 | 0.140 |
Why?
| | HEK293 Cells | 1 | 2021 | 750 | 0.140 |
Why?
| | Cytokines | 6 | 2026 | 2081 | 0.140 |
Why?
| | Collagen Type I | 1 | 2019 | 144 | 0.140 |
Why?
| | Kupffer Cells | 1 | 2018 | 52 | 0.140 |
Why?
| | Hepatitis | 1 | 2018 | 43 | 0.140 |
Why?
| | Aged | 12 | 2026 | 26432 | 0.140 |
Why?
| | Neoplasm Metastasis | 1 | 2021 | 693 | 0.140 |
Why?
| | Membrane Proteins | 2 | 2021 | 1130 | 0.140 |
Why?
| | Cholesterol Esters | 2 | 2022 | 7 | 0.140 |
Why?
| | Aortitis | 1 | 2018 | 10 | 0.130 |
Why?
| | Arginine | 1 | 2019 | 264 | 0.130 |
Why?
| | Cytotoxicity, Immunologic | 1 | 2018 | 224 | 0.130 |
Why?
| | Aging | 3 | 2025 | 1996 | 0.130 |
Why?
| | Neoplasm Transplantation | 3 | 2024 | 238 | 0.130 |
Why?
| | Single-Chain Antibodies | 1 | 2017 | 15 | 0.130 |
Why?
| | Interferon Type I | 1 | 2018 | 147 | 0.130 |
Why?
| | Pyridinium Compounds | 1 | 2017 | 31 | 0.130 |
Why?
| | Middle Aged | 13 | 2026 | 36619 | 0.130 |
Why?
| | Transcriptome | 1 | 2024 | 1068 | 0.130 |
Why?
| | Lysine | 1 | 2019 | 303 | 0.120 |
Why?
| | Cells, Cultured | 6 | 2024 | 4118 | 0.120 |
Why?
| | Mutation | 2 | 2025 | 4093 | 0.120 |
Why?
| | Skin Neoplasms | 2 | 2022 | 806 | 0.120 |
Why?
| | Mice, Inbred ICR | 3 | 2026 | 103 | 0.120 |
Why?
| | Lycopodium | 1 | 2016 | 1 | 0.120 |
Why?
| | Lung | 3 | 2026 | 4122 | 0.120 |
Why?
| | Apoptosis | 3 | 2020 | 2439 | 0.120 |
Why?
| | Heterocyclic Compounds, 4 or More Rings | 1 | 2016 | 25 | 0.120 |
Why?
| | Sepsis | 1 | 2022 | 669 | 0.120 |
Why?
| | Kidney Diseases | 1 | 2020 | 428 | 0.110 |
Why?
| | Head and Neck Neoplasms | 1 | 2021 | 563 | 0.110 |
Why?
| | Levofloxacin | 1 | 2015 | 21 | 0.110 |
Why?
| | Sarcoma | 1 | 2018 | 209 | 0.110 |
Why?
| | Free Radical Scavengers | 1 | 2015 | 81 | 0.110 |
Why?
| | Lymphoma | 1 | 2017 | 251 | 0.110 |
Why?
| | Toll-Like Receptor 4 | 2 | 2021 | 277 | 0.110 |
Why?
| | Scavenger Receptors, Class A | 2 | 2011 | 13 | 0.110 |
Why?
| | Quinolines | 1 | 2016 | 191 | 0.110 |
Why?
| | Cytoplasm | 2 | 2026 | 253 | 0.100 |
Why?
| | Mice, Transgenic | 3 | 2026 | 2134 | 0.100 |
Why?
| | Helicobacter Infections | 1 | 2014 | 30 | 0.100 |
Why?
| | Helicobacter pylori | 1 | 2014 | 44 | 0.100 |
Why?
| | Coculture Techniques | 3 | 2021 | 245 | 0.100 |
Why?
| | Serpins | 2 | 2024 | 28 | 0.100 |
Why?
| | Adenocarcinoma | 1 | 2020 | 927 | 0.100 |
Why?
| | Survival Rate | 3 | 2025 | 2092 | 0.090 |
Why?
| | Mice, Knockout, ApoE | 2 | 2024 | 11 | 0.090 |
Why?
| | Hydrogels | 1 | 2019 | 708 | 0.090 |
Why?
| | Acute Lung Injury | 1 | 2015 | 312 | 0.090 |
Why?
| | Cricetinae | 1 | 2012 | 296 | 0.090 |
Why?
| | Gene Expression Profiling | 1 | 2018 | 1792 | 0.080 |
Why?
| | Mannose | 2 | 2023 | 23 | 0.080 |
Why?
| | Antibodies | 2 | 2023 | 400 | 0.080 |
Why?
| | Influenza A virus | 2 | 2026 | 120 | 0.080 |
Why?
| | Ovarian Neoplasms | 1 | 2016 | 604 | 0.080 |
Why?
| | Lymphocyte Activation | 2 | 2025 | 1137 | 0.080 |
Why?
| | Neutrophils | 3 | 2026 | 1133 | 0.070 |
Why?
| | ErbB Receptors | 2 | 2023 | 636 | 0.070 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2015 | 931 | 0.070 |
Why?
| | Influenza, Human | 1 | 2015 | 640 | 0.070 |
Why?
| | Dendritic Cells | 2 | 2026 | 509 | 0.070 |
Why?
| | Survival Analysis | 2 | 2022 | 1378 | 0.070 |
Why?
| | Reactive Oxygen Species | 2 | 2024 | 610 | 0.070 |
Why?
| | Structure-Activity Relationship | 2 | 2020 | 563 | 0.060 |
Why?
| | Inflammation | 4 | 2026 | 2919 | 0.060 |
Why?
| | Molecular Structure | 2 | 2020 | 484 | 0.060 |
Why?
| | Receptor, PAR-2 | 1 | 2026 | 7 | 0.060 |
Why?
| | Epithelial Sodium Channels | 1 | 2026 | 22 | 0.060 |
Why?
| | Retrospective Studies | 4 | 2026 | 17438 | 0.060 |
Why?
| | Perilipin-2 | 1 | 2026 | 41 | 0.060 |
Why?
| | Hep G2 Cells | 1 | 2026 | 74 | 0.060 |
Why?
| | Collagen Type IV | 1 | 2026 | 26 | 0.060 |
Why?
| | Protective Factors | 1 | 2026 | 97 | 0.060 |
Why?
| | Sirtuin 1 | 1 | 2025 | 35 | 0.060 |
Why?
| | Nutrition Assessment | 1 | 2026 | 90 | 0.060 |
Why?
| | Inducible T-Cell Co-Stimulator Ligand | 1 | 2025 | 4 | 0.060 |
Why?
| | Cell Dedifferentiation | 1 | 2025 | 31 | 0.060 |
Why?
| | Fatal Outcome | 1 | 2026 | 302 | 0.060 |
Why?
| | Antigen Presentation | 1 | 2026 | 209 | 0.050 |
Why?
| | Interferon-gamma | 2 | 2021 | 781 | 0.050 |
Why?
| | Human T-lymphotropic virus 1 | 1 | 2025 | 34 | 0.050 |
Why?
| | Podocytes | 1 | 2026 | 80 | 0.050 |
Why?
| | Immunophenotyping | 1 | 2026 | 324 | 0.050 |
Why?
| | Forkhead Transcription Factors | 1 | 2026 | 209 | 0.050 |
Why?
| | PPAR gamma | 1 | 2025 | 182 | 0.050 |
Why?
| | NLR Family, Pyrin Domain-Containing 3 Protein | 1 | 2026 | 167 | 0.050 |
Why?
| | Inflammasomes | 1 | 2026 | 145 | 0.050 |
Why?
| | Fibroblast Growth Factors | 1 | 2025 | 187 | 0.050 |
Why?
| | Anti-Bacterial Agents | 1 | 2015 | 1942 | 0.050 |
Why?
| | Bevacizumab | 1 | 2025 | 169 | 0.050 |
Why?
| | Mesentery | 1 | 2024 | 44 | 0.050 |
Why?
| | Glutathione | 1 | 2026 | 369 | 0.050 |
Why?
| | Neoplasm Invasiveness | 1 | 2025 | 504 | 0.050 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2020 | 2022 | 0.050 |
Why?
| | Adiponectin | 1 | 2025 | 243 | 0.050 |
Why?
| | Lymphocytes | 1 | 2026 | 379 | 0.050 |
Why?
| | Lymphatic Metastasis | 1 | 2025 | 335 | 0.050 |
Why?
| | Bile Ducts, Intrahepatic | 1 | 2024 | 62 | 0.050 |
Why?
| | Angiogenesis Inhibitors | 1 | 2025 | 239 | 0.050 |
Why?
| | Viral Load | 1 | 2026 | 526 | 0.050 |
Why?
| | Blood-Brain Barrier | 1 | 2025 | 169 | 0.050 |
Why?
| | Bone Marrow Transplantation | 1 | 2024 | 301 | 0.050 |
Why?
| | Enzyme Activation | 1 | 2024 | 759 | 0.050 |
Why?
| | Denervation | 1 | 2022 | 25 | 0.050 |
Why?
| | DNA Mismatch Repair | 1 | 2023 | 54 | 0.050 |
Why?
| | Pancreatectomy | 1 | 2025 | 289 | 0.050 |
Why?
| | Lipocalin-2 | 1 | 2022 | 80 | 0.050 |
Why?
| | Scavenger Receptors, Class B | 1 | 2022 | 14 | 0.050 |
Why?
| | Receptor Protein-Tyrosine Kinases | 1 | 2024 | 227 | 0.040 |
Why?
| | Atrophy | 1 | 2022 | 199 | 0.040 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2025 | 930 | 0.040 |
Why?
| | Administration, Oral | 1 | 2024 | 872 | 0.040 |
Why?
| | Culture Media, Conditioned | 1 | 2022 | 112 | 0.040 |
Why?
| | Cardiovascular Diseases | 1 | 2014 | 2219 | 0.040 |
Why?
| | T-Lymphocytes, Regulatory | 1 | 2025 | 415 | 0.040 |
Why?
| | MCF-7 Cells | 1 | 2021 | 133 | 0.040 |
Why?
| | Mice, Inbred C3H | 1 | 2021 | 252 | 0.040 |
Why?
| | Blotting, Western | 1 | 2023 | 1177 | 0.040 |
Why?
| | Protein-Tyrosine Kinases | 1 | 2024 | 429 | 0.040 |
Why?
| | Arginase | 1 | 2020 | 26 | 0.040 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2023 | 384 | 0.040 |
Why?
| | Mice, Nude | 1 | 2022 | 668 | 0.040 |
Why?
| | Tumor Burden | 1 | 2022 | 326 | 0.040 |
Why?
| | Cerebrovascular Circulation | 1 | 2023 | 293 | 0.040 |
Why?
| | Adult | 5 | 2025 | 41087 | 0.040 |
Why?
| | Myeloid Cells | 1 | 2021 | 149 | 0.040 |
Why?
| | Receptors, Immunologic | 1 | 2021 | 210 | 0.040 |
Why?
| | 3T3 Cells | 1 | 2020 | 152 | 0.040 |
Why?
| | Hepatocytes | 1 | 2021 | 224 | 0.040 |
Why?
| | Cholesterol | 1 | 2022 | 411 | 0.040 |
Why?
| | Enhancer Elements, Genetic | 1 | 2021 | 190 | 0.040 |
Why?
| | NF-kappa B | 2 | 2016 | 674 | 0.040 |
Why?
| | Phagocytosis | 1 | 2021 | 298 | 0.040 |
Why?
| | Endoribonucleases | 1 | 2020 | 80 | 0.040 |
Why?
| | B-Lymphocytes | 1 | 2025 | 887 | 0.040 |
Why?
| | Carcinogenesis | 1 | 2021 | 226 | 0.040 |
Why?
| | Antibodies, Neutralizing | 1 | 2022 | 348 | 0.040 |
Why?
| | Glycosylation | 1 | 2019 | 177 | 0.040 |
Why?
| | Pancreaticoduodenectomy | 1 | 2020 | 149 | 0.040 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2020 | 429 | 0.040 |
Why?
| | RAW 264.7 Cells | 1 | 2018 | 51 | 0.030 |
Why?
| | Minimally Invasive Surgical Procedures | 1 | 2020 | 196 | 0.030 |
Why?
| | Cell Death | 1 | 2020 | 379 | 0.030 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2020 | 299 | 0.030 |
Why?
| | Fibrin | 1 | 2019 | 84 | 0.030 |
Why?
| | RNA, Messenger | 1 | 2026 | 2791 | 0.030 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2018 | 64 | 0.030 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2020 | 545 | 0.030 |
Why?
| | Antibodies, Monoclonal | 1 | 2025 | 1512 | 0.030 |
Why?
| | Serum Albumin | 1 | 2018 | 147 | 0.030 |
Why?
| | Doxorubicin | 1 | 2020 | 416 | 0.030 |
Why?
| | Rats, Sprague-Dawley | 1 | 2023 | 2537 | 0.030 |
Why?
| | Tyrphostins | 1 | 2017 | 18 | 0.030 |
Why?
| | Interleukin 1 Receptor Antagonist Protein | 1 | 2018 | 253 | 0.030 |
Why?
| | Peptide Library | 1 | 2017 | 91 | 0.030 |
Why?
| | Combined Modality Therapy | 1 | 2020 | 1271 | 0.030 |
Why?
| | Neoplasm Grading | 1 | 2018 | 313 | 0.030 |
Why?
| | Necrosis | 1 | 2018 | 243 | 0.030 |
Why?
| | Chemokine CCL4 | 1 | 2017 | 31 | 0.030 |
Why?
| | Protein Stability | 1 | 2017 | 180 | 0.030 |
Why?
| | Receptors, Interleukin-6 | 1 | 2017 | 49 | 0.030 |
Why?
| | Age Factors | 1 | 2024 | 3347 | 0.030 |
Why?
| | Protein Multimerization | 1 | 2017 | 201 | 0.030 |
Why?
| | Caspase 3 | 1 | 2017 | 240 | 0.030 |
Why?
| | Follow-Up Studies | 1 | 2025 | 5439 | 0.030 |
Why?
| | Protein Domains | 1 | 2017 | 315 | 0.030 |
Why?
| | Protein Binding | 1 | 2022 | 2244 | 0.030 |
Why?
| | Kaplan-Meier Estimate | 1 | 2018 | 970 | 0.030 |
Why?
| | Autoantibodies | 1 | 2023 | 1500 | 0.030 |
Why?
| | Collagen | 1 | 2018 | 460 | 0.030 |
Why?
| | Fibrosis | 1 | 2018 | 568 | 0.030 |
Why?
| | Lymphocyte Count | 1 | 2015 | 167 | 0.030 |
Why?
| | Recombinant Proteins | 1 | 2018 | 1361 | 0.030 |
Why?
| | Fluoroquinolones | 1 | 2015 | 44 | 0.030 |
Why?
| | Endothelial Cells | 1 | 2021 | 876 | 0.030 |
Why?
| | Inflammation Mediators | 1 | 2018 | 508 | 0.030 |
Why?
| | Cell Differentiation | 2 | 2014 | 1982 | 0.030 |
Why?
| | Early Detection of Cancer | 1 | 2020 | 506 | 0.030 |
Why?
| | Drug Evaluation, Preclinical | 1 | 2015 | 195 | 0.030 |
Why?
| | Rats | 1 | 2023 | 5586 | 0.030 |
Why?
| | Receptors, LDL | 1 | 2014 | 53 | 0.030 |
Why?
| | Amino Acid Sequence | 1 | 2017 | 2092 | 0.020 |
Why?
| | Case-Control Studies | 1 | 2021 | 3647 | 0.020 |
Why?
| | Nitric Oxide Synthase Type III | 1 | 2014 | 199 | 0.020 |
Why?
| | RNA, Bacterial | 1 | 2014 | 183 | 0.020 |
Why?
| | DNA, Bacterial | 1 | 2014 | 319 | 0.020 |
Why?
| | Pyridines | 1 | 2017 | 610 | 0.020 |
Why?
| | Muscle, Skeletal | 1 | 2022 | 1818 | 0.020 |
Why?
| | Obesity | 1 | 2025 | 3131 | 0.020 |
Why?
| | Interferon Regulatory Factor-3 | 1 | 2011 | 16 | 0.020 |
Why?
| | Biomarkers | 1 | 2023 | 4340 | 0.020 |
Why?
| | Sequence Deletion | 1 | 2011 | 190 | 0.020 |
Why?
| | Brain | 1 | 2023 | 2991 | 0.020 |
Why?
| | Nitric Oxide | 1 | 2015 | 883 | 0.020 |
Why?
| | Child, Preschool | 1 | 2025 | 11913 | 0.020 |
Why?
| | Treatment Outcome | 1 | 2025 | 11821 | 0.020 |
Why?
| | Gene Expression Regulation | 1 | 2019 | 2599 | 0.020 |
Why?
| | Shock, Septic | 1 | 2011 | 230 | 0.020 |
Why?
| | Oxidative Stress | 1 | 2015 | 1369 | 0.020 |
Why?
| | Cell Nucleus | 1 | 2011 | 584 | 0.020 |
Why?
| | Lipopolysaccharides | 1 | 2011 | 861 | 0.020 |
Why?
| | Quality of Life | 1 | 2020 | 3200 | 0.020 |
Why?
| | Proportional Hazards Models | 1 | 2011 | 1331 | 0.020 |
Why?
| | Child | 1 | 2025 | 22693 | 0.010 |
Why?
|
|
Fujiwara's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|